Phase 1/2 Study of Dual-Target CAR-NK Cells in Recurrent Ovarian Cancer
Could New Cell Therapy Change the Game for Women with Recurrent Ovarian Cancer?
This Phase 1/2 trial assesses the safety and preliminary efficacy of dual-target CAR-NK cells in recurrent ovarian cancer, focusing on dose-…
Women with recurrent ovarian cancer may find new hope in a trial testing dual-target CAR-NK cells designed to attack tumors that resist stan…
RAD51-foci Score Predicts Olaparib Efficacy in Advanced HER2-negative Breast Cancer
Could a Simple Test Help Tailor Breast Cancer Treatment?
Phase II study shows RAD51-foci score predicts olaparib response in BRCA1/2, PALB2, RAD51C/D mutated breast cancer. Study enrolled 65 patien…
A new test may help doctors choose the right drug sooner for women with advanced breast cancer who have specific genetic mutations.
Raloxifene SNP Study: Investigating ER and UGT Gene Impact on Breast Cancer Outcomes
Can a Common Breast Cancer Drug Work Better for Some Patients?
This Phase 2/3 trial examines the relationship between ER and UGT SNPs and Raloxifene's efficacy and side effects in 600 BC-LCIS patients. R…
A study is testing if genetic markers can predict which breast cancer patients respond best to Raloxifene, potentially tailoring treatment f…